Literature DB >> 7666053

Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells.

W Biernat1, A Aguzzi, U Sure, J W Grant, P Kleihues, M E Hegi.   

Abstract

Gliosarcomas are morphologically heterogeneous tumors of the central nervous system composed of gliomatous and sarcomatous components. The histogenesis of the latter is still a matter of debate. As mutations of the p53 tumor suppressor gene represent an early event in the development of gliomas, we attempted to determine whether both components of gliosarcomas share identical alterations of the p53 gene. Using single-strand conformation analysis (SSCA) and direct DNA sequencing of the p53 gene, we analyzed dissected gliomatous and sarcomatous parts of 12 formalin-fixed, paraffin-embedded gliosarcomas. The two tumors that contained a p53 alteration were found to carry the identical mutation (exon 5; codon 151, CCC-->TCC; codon 173, GTG-->GTA) in the gliomatous and the sarcomatous components. These findings suggest a common origin of the two cellular components from neoplastic glial cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666053     DOI: 10.1097/00005072-199509000-00006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  37 in total

1.  Gliosarcoma: A rare primary CNS tumor. Presentation of two cases.

Authors:  José Pardo; Mauricio Murcia; Felip García; Arnaldo Alvarado
Journal:  Rep Pract Oncol Radiother       Date:  2010-07-07

2.  Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.

Authors:  Piotr Rieske; Magdalena Zakrzewska; Wojciech Biernat; Jacek Bartkowiak; Arthur Zimmermann; Paweł Piotr Liberski
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 3.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

4.  Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Authors:  J Castelli; L Feuvret; Q C Haoming; J Biau; E Jouglar; A Berger; G Truc; F Llamas Gutierrez; X Morandi; P J Le Reste; F Thillays; D Loussouarn; E Nouhaud; G Crehange; D Antoni; E Vauleon; R de Crevoisier; G Noel
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

5.  C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.

Authors:  David Cachia; Khalida Wani; Marta Penas-Prado; Adriana Olar; Ian E McCutcheon; Robert S Benjamin; Terri S Armstrong; Mark R Gilbert; Kenneth D Aldape
Journal:  Brain Tumor Pathol       Date:  2014-11-12       Impact factor: 3.298

6.  Gliosarcoma with primitive neuroectodermal, osseous, cartilage and adipocyte differentiation: a case report.

Authors:  Kun Yao; Xue-Ling Qi; Xi Mei; Tao Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

7.  Gliosarcomas: analysis of 11 cases do two subtypes exist?

Authors:  Maurizio Salvati; Emanuela Caroli; Antonino Raco; Felice Giangaspero; Roberto Delfini; Luigi Ferrante
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors.

Authors:  Piotr Rieske; Ewa Golanska; Magdalena Zakrzewska; Sylwester Piaskowski; Krystyna Hulas-Bigoszewska; Magdalena Wolańczyk; Malgorzata Szybka; Monika Witusik-Perkowska; Dariusz J Jaskolski; Krzysztof Zakrzewski; Wojciech Biernat; Barbara Krynska; Pawel P Liberski
Journal:  BMC Cancer       Date:  2009-02-14       Impact factor: 4.430

9.  Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo.

Authors:  Ana C deCarvalho; Kevin Nelson; Nancy Lemke; Norman L Lehman; Ali S Arbab; Steven Kalkanis; Tom Mikkelsen
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

Review 10.  Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity.

Authors:  Seunggu J Han; Isaac Yang; Tarik Tihan; Michael D Prados; Andrew T Parsa
Journal:  J Neurooncol       Date:  2009-07-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.